Please ENTER to search
Moving an API from development to commercial scale is not just "making more of it." The reactor changes. The mixing changes. Even the raw material lots can behave differently at scale. A process that runs perfectly in a 5L flask can produce a different impurity profile at 2,000L, and the company has to catch that before it reaches patients.
This is why commercial API manufacturing is treated as its own discipline, not an extension of development chemistry. Scale-up, technology transfer, GMP compliance, and supply reliability all have to work together, or the program slows down.
This guide walks through the eight challenges that show up most often, and the practical steps that help a company move through them without losing months to avoidable problems.
Scale-up changes the physics of a reaction, not just the volume.
Heat transfer, mixing time, and mass transfer all behave differently in a large reactor than in a small one. A reaction that dissipates heat easily at bench scale can develop a hot spot at commercial scale, simply because the vessel has less surface area relative to its volume.
This can shift yield, change impurity levels, or extend cycle time. None of these problems show up until the process actually runs at a larger scale, which is why scale-up needs its own risk assessment, not just a bigger version of the development protocol.
One good batch does not prove a process is ready for commercial supply. Regulators, and pharmaceutical customers, expect the tenth batch to look like the first.
Small sources of variation add up. A raw material lot can differ slightly from the last one. Equipment can perform differently after routine maintenance. An operator can run a step a few minutes faster or slower than the written procedure describes.
None of these differences are dramatic on their own. Together, they can shift yield or impurity levels enough to matter. Reproducibility depends on tight operating ranges, clear in-process checks, and consistent training, not just a well-written batch record.
Technology transfer is where development knowledge either survives the move to manufacturing, or gets lost.
A transfer package should include more than the process steps. It needs the reasoning behind key parameters, known failure points, equipment quirks discovered during development, and the analytical methods used to test the material.
When that reasoning is missing, the manufacturing site has to rediscover it, usually during an investigation after something goes wrong. A well-run transfer takes real coordination between the development team, the manufacturing site, and quality. It is not a document handoff.
Commercial API production sits inside a regulated system from the first batch onward.
GMP requirements shape how materials are handled, how equipment is qualified, how deviations are investigated, and how changes are approved. These are not separate checklists. They work together, and gaps between them are a common source of inspection findings.
A company that treats GMP as something to prepare for before an inspection is already behind. Strong documentation, clear change control, and thorough deviation investigations need to run continuously, not just when an audit is scheduled.
Meeting a specification does not guarantee a material behaves the same way every time.
Particle size, moisture content, and impurity profile can all sit within spec while still shifting how a material reacts. Moisture in particular is an easy thing to overlook, and a common cause of unexpected yield variation in hygroscopic intermediates.
Supplier qualification should go beyond checking a Certificate of Analysis. Testing incoming material against the properties that actually affect the process gives a company a real early warning, before a batch is already underway. Choosing a manufacturer with real visibility into its own raw material chain, rather than one that sources through multiple intermediaries, reduces this risk considerably.
Validation proves a process can perform consistently, not just once.
Most validation frameworks describe three stages: designing the process, confirming it performs as intended, and then verifying it continues to perform well after that. The third stage is the one companies most often underinvest in. Three successful validation batches show the process worked three times. They do not prove it will hold up over the next hundred.
A risk-based control strategy helps here. Not every parameter carries the same risk to product quality, so validation effort should focus on the ones that matter most, rather than spreading evenly across everything.
A dependable API process still needs a dependable supply chain around it.
A single delayed raw material shipment, a supplier quality issue, or unexpected equipment downtime can stall production, even when the chemistry itself is working fine. Single-source materials are the most common vulnerability, and they often go unnoticed until the supplier has a problem of their own.
Supply chain reliability means understanding where the real risks sit, not just tracking current inventory levels. That includes lead times, supplier history, and whether a qualified backup source actually exists.
A commercial facility needs the right equipment, but it also needs people who know how to run it.
Reactors, utilities, and containment systems all need to match the chemistry. Just as important, operators need real experience with the process before the first commercial batch, not just a written procedure to follow.
This becomes especially important during technology transfer. Differences between the development setup and the commercial facility are far easier to fix ahead of time than during a live production run.
These eight challenges are connected. Weak process understanding makes scale-up harder. A rushed technology transfer creates raw material and validation problems later. Addressing them early, during development, is far cheaper than fixing them after commercial batches have already exposed the gap.
Good process development builds understanding, not just a working procedure.
That means identifying which steps are sensitive to scale, how raw material variability affects the reaction, and where impurities are most likely to form. This knowledge becomes the foundation for every decision made later, during scale-up and validation.
QbD connects process parameters to product quality in a structured way.
DoE supports this by testing several variables at once, rather than one at a time. This reveals interactions a single-factor study would miss. A process that looks stable when temperature is tested alone can behave differently when temperature and reagent concentration shift together. DoE is built to catch exactly that kind of interaction.
Process Analytical Technology gives visibility into a reaction while it is happening, not just after it finishes.
Tools like in-line FTIR or reaction calorimetry can flag a deviation early enough to correct it mid-batch. PAT is not worth applying to every parameter, though. It earns its value on steps where real-time correction is actually possible.
A strong technology transfer moves in both directions.
The development team understands the chemistry's failure points. The manufacturing team understands the equipment's real limits. A transfer that only flows one way misses half of what actually matters for a smooth first commercial batch.
Not every process step deserves the same level of validation effort.
Identifying which parameters genuinely affect product quality, and which are procedurally necessary but lower risk, keeps validation focused and meaningful, instead of spread evenly across the whole process.
Supplier qualification should be an ongoing process, not a one-time approval.
Regular performance reviews, honest assessment of single-source risk, and realistic lead-time planning all help a company catch supply problems before they become production delays. Outsourcing this to a CDMO partner with an established, audited supply base can remove much of this burden from an in-house team.
Closing the gap between development and commercial-scale reality is easier with a manufacturing partner that has already done it, repeatedly, across regulated markets.
SCL Lifesciences has over three decades of experience developing and manufacturing APIs and advanced intermediates, with around 80% of revenue coming from exports to Europe, the USA, and Japan. Our commercial-scale manufacturing runs across nine pharma blocks at our facility near Chandigarh, India, including a 22-acre greenfield site with Class 100,000 powder processing, supported by process and analytical development work at the SCL Knowledge Centre in Genome Valley, Hyderabad.
Our regulatory track record reflects the markets we serve: US DMF filings, CEP approvals, WHO Geneva empanelment, EU EDMF filings, and additional registrations across Korea, Australia, Taiwan, and Canada, with USFDA audits completed in 2015, 2017, and 2018.
For a pharmaceutical company evaluating a commercial API manufacturing partner, that combination, scale-up experience, regulatory history across multiple agencies, and integrated development-to-commercial capability, is what actually closes the gap this article describes.
Commercial API manufacturing does not usually fail because a company lacks the science. QbD, DoE, and risk-based validation are well-established approaches, and most experienced teams know them.
It fails when the gap between development-scale understanding and commercial-scale reality is not closed in time. A technology transfer that moves the procedure but not the reasoning. A raw material that passes its Certificate of Analysis but still shifts the reaction. A validation plan that proves the process worked three times but not that it will keep working.
Closing that gap starts early, during process development, and continues through technology transfer, validation, and supply chain planning. Companies that get this right reach commercial supply faster, with fewer surprises along the way.
Talk to our CDMO team about your commercial API manufacturing requirements, or explore our API development and manufacturing capabilities in detail.
Scale-up changes how heat, mixing, and mass transfer behave inside the reactor, not just how much material is produced. A reaction can perform well at bench scale and still develop a new impurity or yield issue at commercial scale, because the physical conditions inside a larger vessel are genuinely different. Identifying scale-sensitive parameters before the first large batch, through modeling or targeted small-scale studies, reduces this risk.
Variability usually comes from several small sources adding up: raw material differences between lots, equipment performance changes after maintenance, and slight differences in how a step is executed. Individually, these differences are often minor. Combined, they can shift yield or impurity levels enough to matter. Tight operating ranges, in-process monitoring, and consistent training are the main ways to control this.
For a moderately complex small-molecule API, technology transfer commonly takes several months, and longer if new analytical methods need to be validated at the receiving site. The timeline depends heavily on how well development data explains the reasoning behind key process decisions, not just the steps themselves. A transfer built only on a batch record usually takes longer, because the receiving site has to rediscover missing context.
No. Dual sourcing makes sense when a material has few qualified suppliers globally or a history of supply disruption. For materials with several established suppliers already available, qualifying a second source often costs more than the risk it reduces. The right approach depends on how critical the material is and how exposed the current supply chain actually is.
Continued process verification, the ongoing monitoring stage after the initial validation batches, is the part most companies underinvest in. Passing three validation batches demonstrates the process worked three times. It does not prove the process will remain stable over hundreds of future batches. Real confidence comes from monitoring production performance after validation is complete, not from the validation batches alone.
Request you to provide all details mentioned in the form along with your business requirement. It will help us route your query to the appropriate person.
